Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Robert Koremans M.D. | CEO & Director | 1.81M | -- | 1962 |
| Mr. Luigi Felice La Corte | Group CFO & Exec. Director | 948k | -- | 1969 |
| Ms. Cathrin Petty | Exec. Director | -- | -- | 1973 |
| Mr. Giampiero Mazza | Exec. Director | -- | -- | 1969 |
| Mr. Giorgio De Palma | Exec. Director | -- | -- | 1974 |
| Ms. Federica De Medici | Director of Investor Relations & Corp. Communications | -- | -- | -- |
| Ms. Bibianne Bon | Group Chief Legal Officer | -- | -- | -- |
| Mr. Gabriele Finzi | Exec. VP of Corp. Devel., Licensing & Innovation | -- | -- | -- |
| Mr. Giuseppe Gualazzini | Sr. VP of Group HR | -- | -- | 1959 |
| Mr. Roberto Teruzzi | Exec. VP of Group Industrial Operations | -- | -- | -- |
Recordati Industria Chimica e Farmaceutica S.p.A.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 4,300
Description
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Corporate Governance
Upcoming Events
May 7, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC
Recordati Industria Chimica e Farmaceutica S.p.A. Earnings Date
Recent Events
May 22, 2023 at 12:00 AM UTC
Ex-Dividend Date